Skip to main content

Table 1 Baseline characteristics at continuous renal replacement therapy initiation

From: Urine neutrophil gelatinase-associated lipocalin and urine output as predictors of the successful discontinuation of continuous renal replacement therapy in critically ill patients with acute kidney injury

Clinical variables

Recovery (n = 22)

Non-recovery; CRRT re-initiation (n = 20)

Non-recovery; Haemodialysis initiation (n = 12)

P-value

Male/female

16/6 (73%/27%)

11/9 (55%/45%)

9/3 (75%/25%)

0.56

Age, years

77 [42–83]

70 [51–81]

68 [30–83]

0.84

BMI, kg/m2

26 [19–35]

27 [19–38]

25 [24–37]

0.45

SOFA, highest value

13 [7–18]

15 [11–19]

13 [8–21]

0,20

APACHE II

27 [18–40]

29 [21–43]

26 [18–38]

0.71

SAPS II

56 [30–75]

65 [44–86]

58 [38–78]

0.10

Hypertension

9 (41%)

11 (55%)

7 (58%)

0.76

Malignity

6 (27%)

10 (50%)

2 (17%)

0.56

CVVH/CVVHD

0/22 (0/100%)

4/16 (20/80%)

0/12 (0/100%)

0.14

RIFLE-F

21 (95%)a

20 (100%)

12 (100%)

0.41

Furosemide, mg/day

0 [0–554]

80 [0–534]

100 [0–480]

0.44d

Mean arterial pressure, mmHg

69 [62–85]

70 [63–93]

78 [59–113]

0.23

Creatinine, μmol/L

186 [84–621]

194 [87–531]

238 [90–765]

0.99

Creatinine clearance, ml/min

19 [7–45]

15 [8–27]

17 [5–26]

0.11

C-Reactive Protein (CRP), mg/L

216 [7–454]

139 [13–266]

108 [34–423]

0.18

Urine output, ml/hour b

18 [0–50]

8 [0–97]

0 [0–52]

0.40d

Urine output, ml/day c

398 [103–1488]

326 [8–1750]

120 [13–2550]

0.23d

Noradrenaline, μg/kg/min

0.35 [0.09–1.26]

0.28 [0.07–1.32]

0.12 [0.02–1.10]

0.35d

Nephrotoxic medicine including contrast.

8 (36%)

12 (60%)

6 (50%)

0.18

Presumed primary cause of AKI:

   

0.56

 Prerenal

8 (36%)

5 (25%)

2 (17%)

 Sepsis

12 (55%)

13 (65%)

4 (33%)

 Glomerulonephritis

0

0

1 (8%)

 Rhabdomyolysis

1 (4,5%)

1 (5%)

3 (25%)

 Microthrombosis/vasculitis

1 (4,5%)

1 (5%)

2 (17%)

Primary reason for ICU admission:

   

0.62

 Septic shock/sepsis

9 (41%)

103 (65%)

6 (51%)

 Trauma

1 (5%)

2 (10%)

0

 AKI

5 (23%)

1 (5%)

2 (17%)

 Respiratory failure

4 (18%)

2 (10%)

3 (34%)

 Low cardiac output

3 (14%)

2 (10%)

1 (8%)

Urine-NGAL, μg/L

2645 [279–27,543]

2894 [749–18,537]

3619 [128–30,170]

0.57d

Time, ICU admission to CRRT initiation/study inclusion, days

1 [0–7.4]

2 [0–5.9]

1 [0–12.1]

0.94

  1. P-value was calculated between the recovery and non-recovery (CRRT-re-initiation and haemodialysis) groups. CRRT, continuous renal replacement therapy; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II; CVVH, continuous veno-venous haemofiltration; CVVHD, continuous veno-venous haemodialysis; AKI, acute kidney injury; NGAL, neutrophil gelatinase-associated lipocalin. Categorical variables are expressed as numbers (percentages). Continuous variables are expressed as medians [10–90% quantiles]
  2. a) RIFLE-I was recorded for one patient. b) Mean urine output 6 h before dialysis initiation; if urine output < 5 ml in one hour, then it was recorded as 0 ml. c) Urine output 24 h before CRRT initiation. d) Log10 transformation was used to calculate the p-value